ANN ARBOR, MI--(Marketwire - May 28, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, today announced that it has entered into an option to acquire an exclusive worldwide license to issued and pending patent applications related to additional uses of oral flupirtine for the treatment of a range of ophthalmic, diabetes and diabetes-related therapeutic indications.
